Investigational Drug Details
| Drug ID: | D084 |
| Drug Name: | Coenzyme Q10 |
| Synonyms: | Coenzyme Q-10; Coenzyme Q10; Ubidecarenone |
| Type: | Chemical drug |
| DrugBank ID: | DB09270 |
| DrugBank Description: | Ubidecarenone, also called coenzyme Q10, is a 1,4-benzoquinone. From his name (Q10), the Q refers to the constitutive quinone group, and 10 is related to the number of isoprenyl subunits in its tail. It is a powerful antioxidant, a lipid-soluble and essential cofactor in mitochondrial oxidative phosphorylation. The ubidecarenone is the coenzyme destined for mitochondrial enzyme complexes involved in oxidative phosphorylation in the production of ATP. It is fundamental for cells that have a high metabolic demand. Ubidecarenone is sold as a dietary supplement and is not FDA approved as a drug thus, it is not meant to treat, cure or prevent any disease. FDA does not approve this dietary supplements before sold nor regulate the manufacturing process. |
| PubChem ID: | 5281915 |
| CasNo: | 303-98-0 |
| Repositioning for NAFLD: | Yes |
| SMILES: | C(/C=C(/CC/C=C(/CC/C=C(/CC/C=C(/CC/C=C(/CC/C=C(/CC/C=C(/CC/C=C(/CC/C=C(/CCC=C(C)C)\C)\C)\C)\C)\C)\C)\C)\C)\C)C1=C(C)C(=O)C(=C(C1=O)OC)OC |
| Structure: |
|
| InChiKey: | ACTIUHUUMQJHFO-UPTCCGCDSA-N |
| Molecular Weight: | 863.365 |
| DrugBank Targets: | NADH dehydrogenase [ubiquinone] flavoprotein 3, mitochondrial cofactor; Succinate dehydrogenase [ubiquinone] flavoprotein subunit, mitochondrial cofactor |
| DrugBank MoA: | Ubidecarenone is an essential cofactor in the mitochondrial electron transport chain. Its functions are the acceptance of electrons from the complex I and II and this activity is vital for the production of ATP. It acts as a mobile redox agent shuttling electrons and protons in the electron transport chain. Ubidecarenone also presents antioxidant activity in mitochondria and cellular membranes, protecting against peroxidation of lipid membranes as well as inhibiting oxidation of LDL-cholesterol. |
| DrugBank Pharmacology: | Ubidecarenon has roles in many prysiological process including sulfide oxidation, regulation of mitochondrial permeability transition pore and translocation of protons and calcium ions accross biological membranes. Studies have shown its benefitial effect in treating cancer, statin myopathy, congestive heart failure and hypertension. |
| DrugBank Indication: | The diet supplements containing ubidecarenone are indicated, as stated in the product label, to assist individuals with cardiovascular complaints including congestive heart failure and systolic hypertension. In the product, ubidecarenone is used to increase the cardiac input as well as for the prevention of several other diseases like Parkinson, fibromyalgia, migraine, periodontal disease and diabetes, based on preclinical studies. It is important to highlight that these products are not FDA approved and it is recommended to use under discretion. |
| Targets: | -- |
| Therapeutic Category: | -- |
| Clinical Trial Progress: | Phase 2 on-going (RBR-26cq7n) |
| Latest Progress: | Under clinical trials |
| Trial ID | Source ID | Phases | Status | Study Results | Start Date | Last Update Posted | |
|---|---|---|---|---|---|---|---|
| L0794 | RBR-26cq7n | Not applicable | Recruiting | No Results Available | 21/06/2018 | 7 February 2022 | Details |
| L0909 | IRCT2013071313984N1 | Phase 2 | Not Recruiting | No Results Available | 18/12/2013 | 22 February 2018 | Details |
| L0919 | IRCT201206094105N8 | Phase 2 | Not Recruiting | No Results Available | 15/06/2013 | 22 February 2018 | Details |
| L0920 | IRCT201305254105N12 | Phase 2 | Not Recruiting | No Results Available | 15/06/2013 | 22 February 2018 | Details |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Article ID | PMID | Source | Title | |
|---|---|---|---|---|
| A03391 | 34019353 | Vopr Pitan | [Specialized products for dietary correction of the diet of patients with non-alcoholic steatohepatitis]. | Details |
| A05802 | 33114148 | Int J Mol Sci | Coenzyme Q10 Supplementation for the Reduction of Oxidative Stress: Clinical Implications in the Treatment of Chronic Diseases. | Details |
| A05903 | 33080906 | Medicina (Kaunas) | Silymarin in Combination with Vitamin C, Vitamin E, Coenzyme Q10 and Selenomethionine to Improve Liver Enzymes and Blood Lipid Profile in NAFLD Patients. | Details |
| A07725 | 32375340 | Int J Mol Sci | Coenzyme Q10 Supplementation Improves Adipokine Levels and Alleviates Inflammation and Lipid Peroxidation in Conditions of Metabolic Syndrome: A Meta-Analysis of Randomized Controlled Trials. | Details |
| A11626 | 30813440 | Nutrients | Effect of Fish Oil Supplementation on Hepatic and Visceral Fat in Overweight Men: A Randomized Controlled Trial. | Details |
| A11713 | 30781472 | Antioxidants (Basel) | Coenzyme Q10 and Degenerative Disorders Affecting Longevity: An Overview. | Details |
| A11932 | 30675881 | Food Funct | Coenzyme Q10 attenuates high-fat diet-induced non-alcoholic fatty liver disease through activation of the AMPK pathway. | Details |
| A13037 | 30171034 | Dis Model Mech | Idebenone and coenzyme Q10 are novel PPARα/γ ligands, with potential for treatment of fatty liver diseases. | Details |
| A13089 | 30142943 | Nutrients | Nutraceutical Approach to Non-Alcoholic Fatty Liver Disease (NAFLD): The Available Clinical Evidence. | Details |
| A20098 | 26156412 | J Am Coll Nutr | Functions of Coenzyme Q10 Supplementation on Liver Enzymes, Markers of Systemic Inflammation, and Adipokines in Patients Affected by Nonalcoholic Fatty Liver Disease: A Double-Blind, Placebo-Controlled, Randomized Clinical Trial. | Details |
| A21262 | 25450583 | Arch Med Res | Oral coenzyme Q10 supplementation in patients with nonalcoholic fatty liver disease: effects on serum vaspin, chemerin, pentraxin 3, insulin resistance and oxidative stress. | Details |
| A28287 | 15784031 | Am J Gastroenterol | Systemic markers of lipid peroxidation and antioxidants in patients with nonalcoholic Fatty liver disease. | Details |
| A50696 | 35296520 | Open Heart | Coenzyme Q10 deficiency can be expected to compromise Sirt1 activity. | Details |
| A52308 | 28811612 | Sci Rep | Coenzyme Q10 Improves Lipid Metabolism and Ameliorates Obesity by Regulating CaMKII-Mediated PDE4 Inhibition. | Details |